Fetal ConditionsNCT07188324
Assessment of Mean Fetal Kidney Length as a Reliable Parameter for Accurate Estimation of Gestational Age in Late 2nd and 3rd Trimesters
An observational study of Fetal Conditions, run by Cairo University at 1 site in Egypt.
Trial summary
Accurate GA estimation is necessary when early termination of pregnancy is necessary as soon as the fetus becomes mature e.g. cases of pre-eclampsia, chronic renal disease, severe intrauterine growth retardation (IUGR), diabetes and placenta praevia centralis. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Fetal Conditions
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 21 Jul 2024to 1 Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Child, Adult, Older adult
Study population: Healthy pregnant women at their late second and third trimester by reliable LMP who will meet the inclusion criteria, attend the fetal medicine Unit at Cairo University Hospital and consent to participate in this study.
Who may be able to join
- All healthy women with viable normal singleton pregnancies in their late second and third trimesters (24 weeks - 40 weeks) calculated from their last menstrual period.
- Women who will sure of the dates of their last menstrual period (1st day) and/or those with first obstetrics dating using crown rump length (CRL). 3- Women with regular menstrual cycle in last three months before their last menstrual period.
Who cannot join
- Women with high-risk pregnancies such as preeclampsia, diabetes, hypertension, polyhydramnios.
- ❖ Maternal:
- Multiple pregnancies.
- Gross maternal obesity.
- ❖ Fetal:
- Fetus with congenital anomalies especially renal anomalies.
Show all 9Show fewer
- Fetuses with abnormal renal morphology (a genesis, hypoplasia, cysts, nephromegaly, polycystic kidney, hydronephrosis, etc.…
- Fetuses with renal pelvic dilatation of 5 mm or greater, obscured adrenal and renal border.
- Fetus with growth abnormalities (intrauterine growth retardation or macrosomia).
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Faculty of Medicine, Cairo University
Giza, Cairo Governorate, 4240310
About this study
Official title: Fetal Kidney Length and Gestational Age in Late 2nd and 3rd Trimesters
Accurate GA estimation is necessary when early termination of pregnancy is necessary as soon as the fetus becomes mature e.g. cases of pre-eclampsia, chronic renal disease, severe intrauterine growth retardation (IUGR), diabetes and placenta praevia centralis. Accurate GA estimation is also necessary where certain tests need to be performed for example amniotic fluid and serum assays, chorionic villus sampling and to plan fetal therapies. (Gupta DP et al., 2013)
Read the detailed description
There are number of parameters used to calculate gestational age, but the most commonly used by all sonologists is a composite gestational age obtained by biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL) in the second and third trimesters (Jae SS et al., 2007). Even these may not provide gestational age with great accuracy owing to discrepancies in late-trimester scans and intrauterine growth restriction (IUGR).
Fetal kidney shows steady growth of 1.1 mm/ gestational week throughout the pregnancy unaffected by any underlying growth abnormalities (Ahmadi et al., 2015). By prenatal ultrasound, identification of either one or both kidneys is possible in 90% of cases in the 17th week of gestation and in 95% of cases after the 20th week. Although kidney size, as for all fetal organs, is affected by growth variations, these appear to predominantly affect only anterior- posterior and transverse diameters (width of kidney) (Callen A., 2008). However, its length shows no significant change with any underlying medical condition (Kansaria and Parulekar, 2010).Fetal kidney length (FKL) has recently been found to have a strong correlation with gestational age. According to the investigations, the fetal kidney length may be utilized to estimate gestational age when dates are ambiguous or when women seek ultrasound fetal biometry dating during the third trimester itself (Kansaria J et al., 2009). Fetal kidney length (FKL), according to a number of studies, closely corresponds with gestational age in the third trimester. Although ultrasound textbooks frequently include tables of various sizes, the fetal kidney has not received much research as a biometric criterion for estimating gestational age(Goyal L et al., 2016).
This study aims to assess the uses of the mean fetal kidney length as reliable parameter for accurate determination of gestational age in late 2nd and/or 3rd trimesters (24 weeks - 40 weeks) in cases who are not sure about their last menstrual period and need proper management of any health problem such as preeclampsia, diabetes or fetal growth abnormality.
- Conditions
- Fetal Conditions
- Keywords
- Fetal kidney - length-gestational age -2D- ultrasound
What is being measured
The primary outcome is the main question the study is designed to answer.
Accuracy of estimation of mean fetal kidney length in comparison with other parameters
Estimation of the gestational age (GA) in weeks by measurement of mean fetal kidney length (MFKL)in mm and detect its accuracy in correlation with gestational age derived from other traditional fetal parameters (BPD, HC, AC\& FL) in mm and actual gestational age derived from first day of last menstrual period.
Measured: 18months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2025
- Study start21 Jul 2024
- Primary completion21 Jan 2026
- Study completion1 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fetal ConditionsStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shaimaa Mostafa Mohammed Refaay El shemy, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07188324
- Sponsor's protocol ID
- Fetal kidney length by 2D us
- Status last verified
- Feb 2026
- First submitted
- 12 Sep 2025
- Last updated
- 2 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fetal Kidney Length and Gestational Age in Late 2nd and 3rd Trimesters
- ClinicalTrials.gov ID
- NCT07188324
- Acronym / sponsor ID
- Fetal kidney length by 2D us
- Conditions
- Fetal Conditions
- Keywords
- Fetal kidney - length-gestational age -2D- ultrasound
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 21 Jul 2024 (actual)
- Primary completion
- 21 Jan 2026 (actual)
- Study completion
- 1 Feb 2026 (actual)
- First posted
- 23 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Accurate GA estimation is necessary when early termination of pregnancy is necessary as soon as the fetus becomes mature e.g. cases of pre-eclampsia, chronic renal disease, severe intrauterine growth retardation (IUGR), diabetes and placenta praevia centralis. Accurate GA estimation is also necessary where certain tests need to be performed for example amniotic fluid and serum assays, chorionic villus sampling and to plan fetal therapies. (Gupta DP et al., 2013)
Detailed description
There are number of parameters used to calculate gestational age, but the most commonly used by all sonologists is a composite gestational age obtained by biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL) in the second and third trimesters (Jae SS et al., 2007). Even these may not provide gestational age with great accuracy owing to discrepancies in late-trimester scans and intrauterine growth restriction (IUGR).
Fetal kidney shows steady growth of 1.1 mm/ gestational week throughout the pregnancy unaffected by any underlying growth abnormalities (Ahmadi et al., 2015). By prenatal ultrasound, identification of either one or both kidneys is possible in 90% of cases in the 17th week of gestation and in 95% of cases after the 20th week. Although kidney size, as for all fetal organs, is affected by growth variations, these appear to predominantly affect only anterior- posterior and transverse diameters (width of kidney) (Callen A., 2008). However, its length shows no significant change with any underlying medical condition (Kansaria and Parulekar, 2010).Fetal kidney length (FKL) has recently been found to have a strong correlation with gestational age. According to the investigations, the fetal kidney length may be utilized to estimate gestational age when dates are ambiguous or when women seek ultrasound fetal biometry dating during the third trimester itself (Kansaria J et al., 2009). Fetal kidney length (FKL), according to a number of studies, closely corresponds with gestational age in the third trimester. Although ultrasound textbooks frequently include tables of various sizes, the fetal kidney has not received much research as a biometric criterion for estimating gestational age(Goyal L et al., 2016).
This study aims to assess the uses of the mean fetal kidney length as reliable parameter for accurate determination of gestational age in late 2nd and/or 3rd trimesters (24 weeks - 40 weeks) in cases who are not sure about their last menstrual period and need proper management of any health problem such as preeclampsia, diabetes or fetal growth abnormality.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Sex
- Female only
- Age groups
- Child, Adult, Older adult
- Study population
- Healthy pregnant women at their late second and third trimester by reliable LMP who will meet the inclusion criteria, attend the fetal medicine Unit at Cairo University Hospital and consent to participate in this study.
Key inclusion criteria (2 listed)
- All healthy women with viable normal singleton pregnancies in their late second and third trimesters (24 weeks - 40 weeks) calculated from their last menstrual period.
- Women who will sure of the dates of their last menstrual period (1st day) and/or those with first obstetrics dating using crown rump length (CRL). 3- Women with regular menstrual cycle in last three months before their last menstrual period.
Key exclusion criteria (9 listed)
- Women with high-risk pregnancies such as preeclampsia, diabetes, hypertension, polyhydramnios.
- Multiple pregnancies.
- Gross maternal obesity.
- Fetus with congenital anomalies especially renal anomalies.
- Fetuses with abnormal renal morphology (a genesis, hypoplasia, cysts, nephromegaly, polycystic kidney, hydronephrosis, etc.…
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Accuracy of estimation of mean fetal kidney length in comparison with other parameters
Time frame: 18months
Estimation of the gestational age (GA) in weeks by measurement of mean fetal kidney length (MFKL)in mm and detect its accuracy in correlation with gestational age derived from other traditional fetal parameters (BPD, HC, AC\& FL) in mm and actual gestational age derived from first day of last menstrual period.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
Related trials for Fetal Conditions
Recruiting
The Value of Advanced Imaging Sequences for Fetal MRI in Clinical Practice
Fetal Conditions
Recruiting
The Effect of Stress Ball Intervention During Non-Stress Test on Anxiety and Fetal Well-Being in High-Risk Pregnancy
Anxiety, Fetal Conditions
Recruiting
A Prospective Study on the Role of Karl Storz Curved and Straight Fetoscopes (11508AAK and 11506AAK) for Fetoscopic Intrauterine Procedures
Fetal Conditions, Maternal; Procedure
Active, not recruiting
An Optimized Programming of Healthy Children (APPROACH)
Pregnancy, Obesity
Not yet recruitingObservational study
Optimization of Cervical Collections in Pregnancy
Cervix; Pregnancy, Inherited Genetic Conditions (Diagnosis)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fetal Conditions, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Accuracy of estimation of mean fetal kidney length in comparison with other parameters (time frame: 18months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026; AzTrials last refreshed its copy on 7 Nov 2026.